<DOC>
	<DOCNO>NCT00805142</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety pharmacokinetics ( drug absorb body , distribute within body , remove body time ; explore body drug ) tapentadol prolong release ( JNS024PR , PR ) participant moderate severe cancer ( abnormal tissue grow spread body kill ) pain .</brief_summary>
	<brief_title>Phase 2 Study Tapentadol Prolonged Release Cancer Pain Participants</brief_title>
	<detailed_description>This Phase 2 open-label ( people know identity intervention ) , multi-centric ( conducted one center ) , non-comparative , optional dose-titration study tapentadol PR Japanese participant cancer pain . This study consist Screening period ( 3 7 day ) , Dose adjustment period ( 3 14 day ) , Fixed dose period ( 5 day ) Follow-up period ( 7 day ) . Tapentadol PR administer orally ( take mouth ; swallow ) twice daily meal . For participant previously use opioids , initial dose tapentadol PR select depend daily dose opioid completion Screening period . For opioid-naive ( moderate severe cancer pain control adequately non-opioid medication ) participant , initial dose tapentadol PR 25 milligram ( mg ) twice daily . Participants receive dose tapentadol PR first 2 day dose adjustment period Day 3 , dose titrate per Investigator 's discretion Day 14 . After participant receive fix dose regimen 5 day dose used end dose adjustment period . Efficacy primarily evaluate sustained pain control 5 day fix dose phase . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>Opioid switch participant meet follow criterion c : ) Participants cancer pain b ) previously opioid medication ( morphine sustain release preparation [ 120 milligram per day { mg/day } less ] , oxycodone hydrochloride sustain release tablet [ 80 mg/day less ] , fentanyl transdermal [ skin ] application system [ 4.2 mg less ] ) c ) achieve adequate pain control opioid therapy Opioid naive participant meet follow criterion b : ) Participants cancer pain b ) receive pain control therapy opioids ( exclude narcotic antagonist analgesic [ drug use control pain ] ) Definite diagnosis type cancer , notify participant Participants hospitalize treatment period Participant record 11 point Numerical Rating Scale ( NRS ) 100 millimeter ( mm ) Visual Analog Scale ( VAS ) score appropriately throughout study Participants bradyarrhythmia ( slow , irregular heartbeat ) History mild moderate traumatic ( cause damage , like toll use crush tissue ) encephalopathy , cerebral ( cerebrum ) infarction ( death tissue lack blood supply ) transient ischemic ( decreased oxygen tissue [ usually decrease blood flow ] ) attack within 1 year inform consent Previous concurrent epilepsy ( seizure disorder ) convulsive disease accompany disturbance consciousness Previous concurrent alcohol dependence narcotic abuse History active hepatitis ( inflammation liver ) B C within 3 month inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tapentadol</keyword>
</DOC>